Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Zamzam Al-Hashami"'
Autor:
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Publikováno v:
Current Oncology, Vol 30, Iss 6, Pp 5299-5308 (2023)
Introduction: Platinum-based chemotherapy was compared to single-agent pembrolizumab in advanced non-small cell lung cancer (NSCLC) with PDL1 > 50% in KEYNOTE-024. In this trial, it was found that patients who received single-agent pembrolizumab had
Externí odkaz:
https://doaj.org/article/631ecefb6a9c42d9babd395a4cb1a0f4
Autor:
Bonnie Leung, Aria Shokoohi, Zamzam Al-Hashami, Sara Moore, Alexandra Pender, Selina K. Wong, Ying Wang, Jonn Wu, Cheryl Ho
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Over the past decade, there has been increasing availability of novel therapeutics with improved tolerability and efficacy for advanced non-small cell lung cancer (NSCLC). The study goals were: to compare the uptake of systemic th
Externí odkaz:
https://doaj.org/article/959f23cddbbe44d1808c0e562adf61bb
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9744-9752 (2022)
Background: In the ATLANTIS study, second-line lurbinectedin/doxorubicin did not improve overall survival (OS), however patients with a chemotherapy-free interval (CTFI) of ≥180 days had an improved progression free survival (PFS). The objective of
Externí odkaz:
https://doaj.org/article/bbaa81df53e848dd85a20e423523f98f
Autor:
Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Publikováno v:
Current Oncology, Vol 29, Iss 11, Pp 8686-8692 (2022)
Background: A fixed dose of 200 mg of pembrolizumab every 3 weeks (Q3W) is the standard of care for patients with stage IV non-small cell lung cancer (NSCLC) and PDL1 ≥50%. In April 2020, based on pharmacokinetic modeling without formal comparative
Externí odkaz:
https://doaj.org/article/e00a766de58841df86bd311c86c0dc6b
Publikováno v:
Annals of Thoracic Medicine, Vol 17, Iss 4, Pp 189-192 (2022)
Lung cancer is the leading cause of cancer-related death worldwide among both men and women. Although advances in therapy have been made, the 5-year survival rates for lung cancer remain poor, ranging from 10% to 20%. One of the main reasons is late
Externí odkaz:
https://doaj.org/article/51a45bc71e8c4e05914cd214f2985856
Autor:
Aria Shokoohi, Zamzam Al‐Hashami, Sara Moore, Alexandra Pender, Selina K. Wong, Ying Wang, Bonnie Leung, Jonn Wu, Cheryl Ho
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 86-93 (2022)
Abstract The evolution of diagnosis and treatment of advanced nonsmall‐cell lung cancer (NSCLC) has led to increasing the use of targeted therapy and immune checkpoint inhibitors. The study goal was to assess the effect of molecular testing and the
Externí odkaz:
https://doaj.org/article/70deca79bca340efbf913f9b0cbfff99
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionSmall cell lung cancer (SCLC) is a rapidly progressing aggressive malignancy. Durvalumab in CASPIAN and atezolizumab in IMPower133 were found to improve overall survival (OS) for extensive-stage SCLC. Here we evaluate the proportion of re
Externí odkaz:
https://doaj.org/article/a7261db868e64185b5434af9d7db84bc
Autor:
Julia R. Naso, Norbert Banyi, Zamzam Al-Hashami, Jingyao Zhu, Gang Wang, Diana N. Ionescu, Cheryl Ho
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100353- (2021)
Introduction: PD-L1 expression may be used as a biomarker predictive of non-small cell lung carcinoma (NSCLC) response to PD-L1 inhibitor treatment. Spatial and temporal heterogeneity in PD-L1 expression and variation in PD-L1 test interpretation may
Externí odkaz:
https://doaj.org/article/6315ad36587a441a81dda71ea5ffb45c
Autor:
Syeda Sara Tajammul, Syed Furqan Hashmi, Zamzam Al Hashami, Laila Al Masaoudi, Sharjeel Usmani, Asma Naz Nadaf, Layth Mula-Hussain
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 15, Iss , Pp 100317- (2024)
Parathyroid carcinoma is one of the rare causes of primary hyperparathyroidism, comprising less than 1 % of its cases. Diagnosing parathyroid carcinoma typically requires a comprehensive evaluation using clinical, histological, and radiological metho
Externí odkaz:
https://doaj.org/article/ecb76568cad343a48c7f1ae218783cb2
Autor:
Caroline Speers, Jonathan M. Loree, Daniel J. Renouf, Zamzam Al-Hashami, Heather Stuart, Parv Chapani, Howard John Lim, Janine M. Davies, Irene S. Yu, Sharlene Gill
Publikováno v:
Clinical Colorectal Cancer. 21:107-113
Small bowel cancers are rare gastrointestinal malignancies and tumor location impact on outcomes is unclear.A retrospective review was performed on stage I to IV small bowel cancer cases from 2000 to 2017 in British Columbia, Canada. Baseline patient